How Is Guillain-Barré Syndrome Diagnosed: Key Tests

Guillain-Barré syndrome (GBS) is diagnosed through a combination of clinical assessment, a spinal fluid sample, and electrical nerve testing rather than any single definitive lab result. A doctor suspecting GBS typically looks for ascending weakness and diminished reflexes, then confirms the picture with a lumbar puncture showing elevated protein without excess white blood cells and nerve conduction studies that reveal slowed or blocked nerve signaling. What makes the diagnosis tricky is that these tests can come back normal in the first few days, which means timing and clinical judgment matter as much as the test results themselves.

What Doctors Look for First

The hallmark of GBS is rapidly progressive weakness that usually starts in the legs and moves upward, accompanied by reduced or absent deep tendon reflexes. A neurologist evaluates the pattern of weakness, checks reflexes at the knees and ankles, and asks about recent infections, because roughly two-thirds of people with GBS had a respiratory or gastrointestinal illness in the weeks before symptoms appeared. Campylobacter jejuni, a bacterium that causes food poisoning, is the most commonly identified trigger, with serological evidence of recent infection found in roughly 20 to 40 percent of GBS patients.¹ The clinical picture alone can be enough to start treatment, but the tests that follow help confirm the diagnosis, rule out mimics, and guide decisions about how aggressive treatment needs to be.

Several conditions can look a lot like GBS on first presentation, including spinal cord compression, transverse myelitis, and certain metabolic or toxic neuropathies.² That overlap is precisely why the confirmatory tests carry so much weight. A confident diagnosis of GBS usually requires at least two of the three pillars: the right clinical picture, supportive spinal fluid findings, and abnormal nerve conduction studies.

The Lumbar Puncture and What It Shows

A lumbar puncture, commonly called a spinal tap, draws a small sample of cerebrospinal fluid (CSF) from the lower back. In GBS the classic finding is elevated protein in the CSF while the white blood cell count stays normal or near-normal. Neurologists call this “albuminocytologic dissociation,” and it reflects inflammation at the nerve roots without the kind of immune cell invasion you would see in an infection of the nervous system.

About 70 percent of GBS patients show this pattern when data from large cohorts are pooled, but the proportion climbs sharply depending on when the tap is performed.³ In the first day or two of weakness, fewer than half of patients have clearly elevated CSF protein. Wait until the end of the first week and the yield jumps to around 84 percent.⁴ A systematic review pooling nearly 3,000 patients confirmed this time-dependent pattern, finding an overall yield of about 80 percent across studies but only about 48 percent when the tap was done within the first day of onset.⁵

Age complicates interpretation, too. Older adults naturally have somewhat higher CSF protein levels, so what looks like a GBS-related spike in a 25-year-old might fall within the expected range for someone who is 70. Using age-adjusted thresholds rather than a single cutoff catches this issue, though it also lowers the apparent sensitivity of the test.⁴ The practical takeaway is that a normal lumbar puncture does not rule out GBS, especially if it was done early. Many neurologists will repeat the tap a few days later if the clinical picture still fits.

Nerve Conduction Studies and Electromyography

Nerve conduction studies (NCS), sometimes paired with electromyography (EMG), are the electrical tests that measure how fast and how strongly signals travel through peripheral nerves and muscles. In GBS, these studies do two things: they support the diagnosis by showing nerve dysfunction, and they sort patients into subtypes that affect prognosis and treatment planning.⁶

The most common subtype in North America and Europe is acute inflammatory demyelinating polyneuropathy (AIDP), where the immune system strips the protective myelin coating off nerve fibers. On nerve conduction studies, AIDP shows up as slowed conduction velocities, prolonged distal latencies, and conduction block, all signs that the insulation around nerves is damaged. Axonal subtypes, more common in East Asia and often associated with Campylobacter infection, show reduced signal amplitude instead, meaning the nerve fibers themselves are injured rather than just their coating.⁷ Distinguishing between these patterns matters because axonal damage tends to mean a longer and harder recovery.

Like the lumbar puncture, nerve conduction studies can be frustratingly normal during the first few days of illness. In one study, conventional electrophysiology was nondiagnostic in 40 percent of patients tested within the first week.⁸ Even when other findings are still equivocal, some abnormalities tend to show up early. Absent H-reflexes, which test the reflex arc through the spinal cord and back, are the most common early finding, seen in over 85 percent of patients. Abnormal F-waves, which measure nerve signaling along the full length of a motor nerve, are found in about 44 percent early on and have the added value of predicting a more complicated course, including respiratory failure and longer hospitalization.⁹

Why Test Timing Matters So Much

One of the biggest diagnostic pitfalls in GBS is testing too early and trusting a normal result. Both the spinal fluid protein and the nerve conduction abnormalities evolve over the first one to two weeks. A patient seen on day two of weakness might have a normal lumbar puncture, normal nerve conduction studies, and still have GBS. Experienced neurologists know to weigh the clinical exam heavily and to repeat tests when initial results do not match what they are seeing at the bedside.

The Brighton Collaboration developed a tiered set of diagnostic criteria specifically to address this issue. Level 1, the highest certainty, requires bilateral weakness, decreased reflexes, a disease course consistent with GBS, an elevated CSF protein with low white cell count, and nerve conduction findings consistent with a recognized GBS subtype. In a large study of nearly 500 adults, 61 percent of patients with complete data met level 1 criteria, while another 33 percent met level 2, which allows for incomplete nerve conduction or CSF data.¹⁰ In children, the sensitivity of level 1 was 72 percent, rising to 96 percent for level 2.¹¹ The system acknowledges that not every patient will check every diagnostic box, and that waiting for a perfect data set should not delay treatment.

Anti-Ganglioside Antibody Testing

Gangliosides are sugar-fat molecules that sit on the surface of nerve cells. In GBS the immune system sometimes produces antibodies that target specific gangliosides, and testing for these antibodies helps identify subtypes and predict how the disease will behave. In one screening study of 100 GBS patients, 61 percent tested positive for at least one anti-ganglioside antibody.¹²

Specific antibody patterns are linked to specific subtypes. Anti-GM1 IgG antibodies are strongly associated with the axonal subtype (AMAN), where they show a sensitivity of about 86 percent and a specificity of 69 percent.¹³ IgG anti-GM1 antibodies are also independently associated with poorer outcomes, which makes them useful for prognosis on top of diagnosis.¹² Including antibody results can improve the diagnostic sensitivity of formal criteria, especially in patients whose CSF or nerve conduction findings are borderline.¹⁴

Antibody testing is most useful in two situations: when the presentation does not fit the classic pattern and when doctors need to identify the subtype quickly. It is not required for diagnosis in straightforward cases, and many hospitals send samples to reference laboratories, which means results may not return for a week or more. Treatment decisions generally cannot wait that long.

Diagnosing Miller Fisher Syndrome

Miller Fisher syndrome (MFS) is the best-known GBS variant, and it looks nothing like the classic ascending weakness. Instead, people with MFS typically develop double vision from eye-movement paralysis, unsteady gait from cerebellar-type ataxia, and absent reflexes. This triad appears in roughly 80 percent of patients.¹⁵ Because the legs are not weak and the presentation can look like a stroke or brainstem problem, MFS is frequently misdiagnosed initially.

The diagnostic anchor for MFS is the anti-GQ1b antibody, which is present in about 85 percent of patients and is essentially never found in healthy people, giving it a reported specificity of 100 percent.¹⁵ When a doctor suspects MFS, ordering this antibody test can clinch the diagnosis while the CSF and nerve studies may still be ambiguous. Standard GBS diagnostic criteria tend to have lower sensitivity for MFS precisely because the classic findings of limb weakness and high CSF protein are often absent.¹⁴

When MRI Adds Value

MRI is not a first-line diagnostic test for GBS, but it earns its place in specific situations. A lumbosacral MRI with gadolinium contrast can show enhancement of the cauda equina nerve roots, which reflects inflammation and breakdown of the blood-nerve barrier. In a prospective study of 24 GBS patients, nerve root enhancement was found in 83 percent overall and in 95 percent of patients with a typical clinical picture.¹⁶

MRI is most helpful when the nerve conduction studies are equivocal, when the diagnosis is uncertain, or when doctors need to rule out a structural cause of weakness like a spinal cord mass or disc herniation.¹⁷ It also plays a role in pediatric cases, where children may not cooperate with nerve conduction testing and the clinical presentation is sometimes atypical.

Monitoring Breathing and the Heart

Some of the most important “tests” in GBS are not about confirming the diagnosis but about catching life-threatening complications in real time. About a quarter of GBS patients develop respiratory muscle weakness severe enough to require mechanical ventilation, and the decline can happen fast. Bedside measurement of forced vital capacity (how much air someone can blow out after a full breath) is the standard monitoring tool. A falling vital capacity is one of the clearest signals that a patient needs to move to an intensive care unit. Research comparing vital capacity to maximum inspiratory pressure found that the two are linearly related and that inspiratory pressure does not add much early warning beyond what vital capacity already provides.¹⁸

Autonomic dysfunction, meaning the parts of the nervous system that control heart rate, blood pressure, and sweating, is also common and sometimes dangerous. Cardiovascular autonomic testing in GBS patients has shown impaired responses to the Valsalva maneuver, abnormal heart rate variability, and unstable blood pressure with posture changes. At the height of illness, subclinical autonomic involvement affects the vast majority of patients, even those who feel fine otherwise.¹⁹ Fixed, fast heart rates and episodes of profound blood pressure drops are red flags that warrant continuous cardiac monitoring. These autonomic abnormalities tend to improve gradually in parallel with motor recovery.²⁰

Predicting Outcomes Early

Once the diagnosis is established, doctors shift focus to predicting how severe the course will be. The modified Erasmus GBS Outcome Score (mEGOS) is the most widely validated prognostic tool. It uses three inputs collected at the bedside: the patient’s age, whether they had diarrhea before the neurological symptoms started, and the overall strength score on a standardized scale (the Medical Research Council sum score). Higher age, preceding diarrhea, and greater weakness all point to a worse prognosis.²¹

The score can be calculated at hospital admission and again at one week. The one-week version is more accurate, with an area under the curve of 0.84 to 0.87 for predicting whether the patient will be unable to walk at four weeks, three months, or six months.²¹ Higher mEGOS scores also correlate with the likelihood of needing mechanical ventilation and with long-term disability.²² The score does not replace clinical judgment, but it gives care teams a structured way to flag patients who are likely to need aggressive treatment and prolonged rehabilitation.

Diagnostic Challenges in Children

GBS in children presents a particular diagnostic challenge. Young children cannot always describe numbness or tingling, and their refusal to walk may be attributed to hip pain, a viral illness, or a behavioral issue. In one study of pediatric GBS, 40 misdiagnoses were recorded among just 17 patients before the correct diagnosis was reached, with a median overall diagnostic delay of 9 days. The most common wrong diagnoses were orthopedic conditions and viral infections.²³ Children whose weakness developed slowly or who had sensory complaints rather than obvious leg weakness were especially likely to be diagnosed late.

In resource-limited settings, the challenge is compounded by lack of access to nerve conduction studies and immunoglobulin treatment. A study from a low-resource hospital found that no patient received nerve conduction testing and only about 6 percent received intravenous immunoglobulin.²⁴ In these environments, the diagnosis rests almost entirely on clinical features and a lumbar puncture, underscoring how important bedside assessment skills remain when technology is unavailable.

Newer Tools on the Horizon

Nerve Ultrasound

High-resolution ultrasound of peripheral nerves is gaining traction as a quick, painless complement to nerve conduction studies. In GBS, inflammation causes nerves to swell, and ultrasound can measure this enlargement in real time. A meta-analysis found significantly increased nerve cross-sectional area in GBS patients across multiple nerves, with the most prominent enlargement in the cervical nerve roots and the peroneal nerve.²⁵ Studies from China confirmed that cervical root enlargement in particular can distinguish GBS patients from healthy controls with high statistical significance.²⁶ Ultrasound does not replace nerve conduction studies yet, but it offers a way to get early supportive evidence, especially in patients who cannot tolerate electrical testing or when nerve conduction equipment is unavailable. The fact that the swelling is detectable at initial presentation and persists at two weeks makes it a practical bedside option.²⁷

Neurofilament Light Chain

Neurofilament light chain (NfL) is a protein that leaks into the blood when nerve fibers are damaged. Measuring it with a simple blood draw could eventually change how GBS is monitored. A meta-analysis of nine studies found that serum NfL levels in GBS patients were substantially higher than in healthy controls, and levels were especially elevated in patients with axonal subtypes compared to demyelinating ones.²⁸ Higher NfL at admission correlated with greater disease severity and with the odds of a poor long-term outcome.²⁹ NfL is not specific to GBS, as it rises in many neurological conditions, so it works better as a severity and prognostic marker than as a standalone diagnostic test. Still, researchers are optimistic that tracking NfL over time could help gauge whether treatment is working and serve as a concrete measure of nerve damage that existing tests do not easily capture.³⁰

GBS After Cancer Immunotherapy

Immune checkpoint inhibitors, a class of cancer drugs that unleash the immune system against tumors, have created a new clinical context for GBS. The presentation is essentially the same: progressive limb weakness, sensory changes, and absent reflexes developing over days to weeks. The difference is the setting. When a patient on checkpoint inhibitor therapy develops these symptoms, clinicians need to consider drug-related GBS alongside more common causes of neuropathy in cancer patients, such as chemotherapy toxicity or tumor infiltration of nerves.³¹ The diagnostic workup is the same suite of tests: lumbar puncture, nerve conduction studies, and antibody panels. What changes is the urgency. The offending drug usually needs to be stopped, and immunosuppressive treatment may need to be more aggressive. Oncologists and neurologists increasingly collaborate on these cases, and awareness that GBS can be an immune-related adverse event has grown significantly over the past decade.